Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Insider Sells $238,350.00 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) insider Helen Louise Collins sold 5,000 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $47.67, for a total transaction of $238,350.00. Following the transaction, the insider directly owned 25,000 shares of the company’s stock, valued at approximately $1,191,750. This represents a 16.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

• On Wednesday, March 25th, Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $35.10, for a total transaction of $1,404,000.00.
• On Tuesday, March 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $27.76, for a total transaction of $138,800.00.

Bitwise MARA Option Income Strategy ETF Price Performance

NYSEARCA IMRA opened at $15.80 on Friday. Bitwise MARA Option Income Strategy ETF has a 12 month low of $11.99 and a 12 month high of $60.73. The company has a 50-day moving average of $14.05 and a 200-day moving average of $19.51. The company has a market cap of $3.00 million, a P/E ratio of 316.00 and a beta of 3.78.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2?related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.